Leo Raphael J., Barkin Robert L.
Department of Psychiatry, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo; and the Departments of Anesthesiology, Family Medicine, and Pharmacology, The Rush North Shore Pain Center of Rush Presbyterian St. Luke's Medical Center, Chicago, Ill.
Prim Care Companion J Clin Psychiatry. 2003 Jun;5(3):118-123. doi: 10.4088/pcc.v05n0303.
Duloxetine is a novel antidepressant that is anticipated to be clinically available soon. It exerts simultaneous noradrenergic and serotonergic neurotransmitter effects. Because of these influences, it is postulated to have a role in management of pain. DATA SOURCES: An Index Medicus search from 1997 to 2003 was conducted using the search terms duloxetine, Cymbalta, and pain. DATA ANALYSIS: Preclinical animal studies suggest that duloxetine may have a direct analgesic role. Premarketing studies have emphasized its utility in alleviating somatic, specifically pain, complaints among patients with major depression. CONCLUSION: Although promising, these results cannot be generalized to patients with pain disorders; the reasons for this are discussed herein. While duloxetine may be useful among somatizing depressed patients and possibly chronic pain patients with comorbid depression, its analgesic role has yet to be elucidated in future research.
Zotero 插件